



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2177961 C 2007/10/23

(11)(21) **2 177 961**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1994/12/02
(87) Date publication PCT/PCT Publication Date: 1995/06/08
(45) Date de délivrance/Issue Date: 2007/10/23
(85) Entrée phase nationale/National Entry: 1996/05/31
(86) N° demande PCT/PCT Application No.: EP 1994/004023
(87) N° publication PCT/PCT Publication No.: 1995/015169
(30) Priorité/Priority: 1993/12/02 (DEP 43 41 139.8)

(51) Cl.Int./Int.Cl. *A61K 31/80* (2006.01),
A61K 9/107 (2006.01), *A61P 1/04* (2006.01)

(72) Inventeurs/Inventors:
SCHMIDT, ALFRED, DE;
UPMEYER, HANS-JURGEN, DE

(73) Propriétaires/Owners:
SCHMIDT, ALFRED, DE;
UPMEYER, HANS-JURGEN, DE

(74) Agent: KIRBY EADES GALE BAKER

(54) Titre : UTILISATION DE DIMETICONE DANS LE TRAITEMENT DES APHTES ET DE LA STOMATITE
(54) Title: USE OF DIMETICONE FOR TREATING APHTHAE AND STOMATITIS

(57) Abrégé/Abstract:

The invention disclosed relates to treating aphthae and stomatitis by applying dimeticone to the afflicted oral mucosa.





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/80, 31/695	A1	(11) International Publication Number: WO 95/15169 (43) International Publication Date: 8 June 1995 (08.06.95)
(21) International Application Number: PCT/EP94/04023 (22) International Filing Date: 2 December 1994 (02.12.94) (30) Priority Data: P 43 41 139.8 2 December 1993 (02.12.93) DE (71)(72) Applicants and Inventors: SCHMIDT, Alfred [DE/DE]; Leinpfad 2, D-22301 Hamburg (DE). UPMEYER, Hans- Jürgen [DE/DE]; Mauerkircherstrasse 197, D-81925 München (DE). (74) Agent: VOSSIUS & PARTNER; Postfach 86 07 67, D-81634 München (DE).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). 2177961 Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: USE OF DIMETICONE FOR TREATING APHTHAE AND STOMATITIS (57) Abstract The invention disclosed relates to treating aphthae and stomatitis by applying dimeticone to the afflicted oral mucosa.		

USE OF DIMETICONE FOR TREATING APHTHAE AND STOMATITIS

This invention relates to methods for treating aphthae and stomatitis.

Aphthae and stomatitis are inflammatory changes of the oral mucosa which appear in the form of painful tumefactions of oedematous and infiltrative foci covered with a firmly adhering fibrinous film, and ulcera. These tumefactions are roundish and can become as large as lentil beans. Aphthae have multiple etiology and may be caused by infections and allergic reactions, may ensue from internal diseases, or may be of a psychosomatic nature. Also, acid-containing caustic food may lead to inflammations of the oral mucosa. Frequently, medicaments, particularly chemotherapy, may also lead to blister formation in the mouth. Radiation may also be the cause of aphthae. Moreover, smoking may lead to the formation of stomatitis nicotina.

A mucosa injury may be the result of a self-inflicted bite.

Viral infections may also be the cause of oral aphthae. Thus, DNS-viruses, such as herpes simplex, may cause aphthous stomatitis, which may be recurring, and gingivostomatitis herpetica, resulting in the formation of blisters and ulcerous lesions in the oral cavity.

The therapy of such pathological changes of the oral mucosa depends on the severity of the disease and comprises the treatment of possible primary diseases, the avoidance of mouth-care agents, food or stimulants causing pain, and the topical alleviation of pain by anaesthetic-containing pharmaceuticals, such as AnästhesinTM-containing pharmaceuticals. Moreover, mild, anti-inflammatory washes or corticoid-containing ointments or lozenges are used.

However, there continues to exist a need for a pharmaceutical which is capable of bringing immediate relief from pain and also of prompting the aphthae and stomatitis to heal quickly without, however, inducing possible systemic side effects.

Dimeticone (dimethylpolysiloxane) is at present used to treat flatulence and meteorism. Moreover, the use of dimethylpolysiloxane in the treatment of ulcerous diseases of the stomach and the duodenum and inflammatory diseases of the esophagus and antrum gastritis is known. For instance, WO 90/07930 describes the capability of dimethylpolysiloxane to form and maintain a protective film in the esophagus, the stomach and the duodenum after oral administration. This results in the healing of the aforementioned diseases.

Certain exemplary embodiments can provide use of dimethylpolysiloxane as an active ingredient for the preparation of a pharmaceutical composition for the treatment of aphthae and stomatitis.

Certain exemplary embodiments can provide a pharmaceutical composition for the treatment of aphthae and stomatitis comprising dimethylpolysiloxane as an active ingredient and a pharmaceutically acceptable carrier, diluent or excipient.

2a

Certain exemplary embodiments can provide use of dimethylpolysiloxane for the treatment of aphthae and stomatitis.

The invention is based on the unexpected finding that the application of dimeticone, in particular of dimeticone-containing solutions, onto inflamed oral mucosa caused by aphthae or stomatitis leads to an immediate relief from pain, this relief lasting for 3 to 4 hours after application. Moreover, it has been found that the application of a dimeticone liquid three times a day resulted in fast healing of the aphthae. A marked improvement could already be observed after 2 days. Moreover, no undesired side effects were found. Furthermore, dimeticone has a

neutral taste and does not have any adverse effects on taste sensation during food intake.

Dimeticone may be applied according to the invention in the form of tablets, capsules, patches, emulsions, suspensions and powders for oral administration. It is preferably in liquid form and may be applied together with a biologically acceptable carrier, such as highly dispersed silicon dioxide, and/or an emulsion, such as an emulsion of water and a salt of a fatty acid (e.g. magnesium stearate). Such compositions may be administered to humans and animals in a safe and effective amount to elicit the desired result. Optionally, the usual flavors, such as peppermint or curled mint fragrant substances, or sweeteners such as AspartameTM or sodium cyclamate, may be added to the mixture.

Dosage levels and requirements may be chosen by those of ordinary skill in the art from the available methods and techniques. Specific dosage and treatment regimens will depend upon factors such as the severity and course of the aphthae or disposition thereto.

In order that this invention be more fully understood, the following example is set forth. This example is for the purpose of illustration only, and is not to be construed as limiting the scope of the invention in any way.

Example

Preparation of treatment composition

100 g of dimethylpolysiloxane, 12 g of highly dispersed silicon dioxide and 100 g of magnesium stearate are melted in a water bath and stirred to form an emulsion. The emulsion is then diluted with water for the preparation of a liquid pharmaceutical which lends itself for administration in the form of drops.

Example of Application

Patient:	male
Age:	46
Diagnosis	erosions of the oral mucosa (aphthae) showing a whitish fibrinous film;
Cause:	unknown; suspected cause: high consumption of citric fruits;
Therapy:	application of the dimeticone-containing liquid onto the aphthae 3 times a day;
Effect:	The application of the dimeticone-containing liquid brought an immediate relief from pain, which lasted for 3 to 4 hours.
Healing:	The application of the dimeticone-containing liquid 3 times a day brought about rapid healing of the aphthae and marked improvement was already recognizable after 2 days. After two more days the erosion was removed.
Side effects:	None
Taste:	The dimeticone-containing liquid had a neutral taste and did not have any adverse effects on taste sensation during food intake.

While we have described an embodiment of this invention, it is apparent that our embodiment may be altered to provide other embodiments which utilize the method of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims, rather than by the specific embodiment which has been presented by way of example.

CLAIMS

1. Use of dimethylpolysiloxane as an active ingredient for the preparation of a pharmaceutical composition for the treatment of aphthae and stomatitis.
2. Use according to claim 1 wherein the aphthae to be treated is stomatitis aphthosa.
3. Use according to claim 1 wherein the composition is in the form of an emulsion.
4. A pharmaceutical composition for the treatment of aphthae and stomatitis comprising dimethylpolysiloxane as an active ingredient and a pharmaceutically acceptable carrier, diluent or excipient.
5. Use of dimethylpolysiloxane for the treatment of aphthae and stomatitis.
6. Use of claim 5 wherein the aphthae to be treated is stomatitis aphthosa.
7. Use of claim 5 wherein the composition is in the form of an emulsion.